A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
Public ClinicalTrials.gov record NCT04483947. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Double Blind, Randomised, Placebo-Controlled, Multi-centre, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2693 in Patients With Non-alcoholic Steatohepatitis (NASH) With Fibrosis Stage 0-3 and Carriers of the PNPLA3 148M Risk Alleles
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with Non-alcoholic Steatohepatitis (NASH) with fibrosis Stage 0 to 3 and who are carriers of the patatin-like phospholipase domain-containing 3 (PNPLA3) 148M risk alleles.
Study identification
- NCT ID
- NCT04483947
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 5, 2020
- Primary completion
- Dec 17, 2023
- Completion
- Dec 17, 2023
- Last update posted
- Jan 16, 2024
2020 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 7
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Chula Vista | California | 91911 | — |
| Research Site | La Mesa | California | 91942 | — |
| Research Site | Montclair | California | 91763 | — |
| Research Site | San Diego | California | 92103 | — |
| Research Site | Doral | Florida | 33166 | — |
| Research Site | Hialeah | Florida | 33014 | — |
| Research Site | Hialeah | Florida | 33016 | — |
| Research Site | Miami Lakes | Florida | 33014 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Morehead City | North Carolina | 28557 | — |
| Research Site | Columbus | Ohio | 43213 | — |
| Research Site | Hershey | Pennsylvania | 17033 | — |
| Research Site | Arlington | Texas | 76012 | — |
| Research Site | Dallas | Texas | 75203 | — |
| Research Site | San Antonio | Texas | 78215 | — |
| Research Site | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04483947, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 16, 2024 · Synced Sep 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04483947 live on ClinicalTrials.gov.